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Abstract
The introduction of interferon beta therapies more than 20 years ago marked a mile-
stone in the treatment of relapsing- remitting multiple sclerosis (RRMS) with a signifi-
cant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and 
perspectives from the early days of disease modifying therapies in MS have improved 
the	knowledge	base	of	MS,	need	for	treatment,	and	patient	care.	The	continuous	de-
velopment of interferons over the past two decades outlines a journey with increased 
understanding of the pharmacodynamics and pharmacokinetic mechanisms of inter-
ferons,	leading	to	innovative	formulations	with	an	improved	benefit/risk	profile.
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1  | INTRODUCTION
Multiple sclerosis (MS) is the most common chronic cause of neu-
rological	 disability	 among	 younger	 adults	 (Compston	 &	 Coles,	
2008;	 Noseworthy,	 Lucchinetti,	 Rodriguez,	 &	 Weinshenker,	 2000).	
Acknowledging	that	until	20	some	years	ago	the	treatment	of	MS	pa-
tients focused mainly on treating relapses with systemic corticosteroids 
and	providing	various	symptomatic	treatment,	the	 introduction	of	 in-
terferon beta therapies in 1993 (interferon beta- 1b) and in 1996 (in-
terferon beta- 1a) fundamentally changed the MS treatment paradigm. 
For	 patients,	 treatment	 transferred	 from	 symptomatic	 management	
into	 disease	modifying	 long-	term	 therapy,	 and	 for	 neurologists	 their	
roles changed from passively observing and awaiting patient worsen-
ing into proactively treating the underlying disease in the MS patients. 
This implied logistical changes to MS care in general with the need for 
improved follow- up.
The interferon betas represent the first class of disease modi-
fying therapies (DMTs) for MS and have contributed considerably 
to the understanding of the immunomodulatory mechanisms in 
MS. Since then several other DMTs have been approved for the 
treatment	of	MS.	However,	with	a	growing	body	of	evidence	on	the	
long- term benefits by reduction of disability progression (Scalfari 
et	al.,	 2010;	Trojano	 et	al.,	 2009),	 reduced	mortality,	 and	 data	 to	
suggest maternal and fetal relative safety in pregnancy outcomes 
(Amato	&	Portaccio,	2015;	Romero,	Lunzmann,	&	Bugge,	2015)	—	
interferons maintain an impor tant role in the treatment of RRMS. 
Furthermore,	 the	 interferon	 betas	 are	 acknowledged	 as	 standard	
of care and have recently acted as an active comparator in two 
different	large	scale	prospective	randomized	controlled	clinical	tri-
als	testing	new	MS	therapies	(Hauser	et	al.,	2017;	Kappos,	Wiendl,	
et	al.,	2015).
The recent introduction of an innovative formulation of interferon 
beta- 1a has improved patient convenience by a markedly reduction in 
number	of	 injections,	 a	 favorable	 risk	profile	building	on	 two	decades	
of	clinical	use,	and	potentially	improved	efficacy	(Calabresi	et	al.,	2014;	
Kieseier	et	al.,	2014).	The	purpose	of	this	paper	is	to	give	a	historic	over-
view	of	interferon	treatment	in	MS,	marking	the	continued	development	
of the drug class for more than two decades after the initial introduc-
tion and acknowledging the history as well as part of the future in MS 
treatment.
The copyright line for this article was changed on 29 June 2017 after original online publication.
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2  | PARADIGM SHIFT IN THE TREATMENT  
OF MS
In patients with RRMS with preserved walking function and with signs 
of	disease	activity,	demonstrated	by	 relapses	over	 the	prior	1	 to	2-	
year	 period,	 interferon	 beta	 therapies	 have	 been	 shown	 to	 reduce	
the number of relapses by an average of 30% compared to placebo 
and in particular the number of severe relapses is reduced (Calabresi 
et	al.,	2014;	Jacobs	et	al.,	1996;	Kieseier	et	al.,	2014;	PRISMS	Study	
Group,	1998;	Rudick	et	al.,	1997;	The	IFNB	Multiple	Sclerosis	Study	
Group,	1993).	Furthermore,	 interferon	beta	delays	the	development	
of permanent neurological disability and disease activity evaluated by 
magnetic resonance imaging (MRI). Patients with the first suspected 
demyelinating episode and typical MS- changes on MRI or less typical 
changes on MRI combined with oligoclonal bands are at high risk of 
developing clinically definite MS (CDMS) over the following period of 
2	years	(Polman	et	al.,	2005).	Treatment	with	interferon	beta	prolongs	
the time to CDMS and reduces relapse rate and disease progression 
(Kappos,	Kuhle,	et	al.,	2015).	The	introduction	of	interferon	betas	for	
the treatment of RRMS represented a paradigm shift in the manage-
ment of MS and fueled a significant interest from the patient com-
munity.	At	that	time	the	criteria	for	interferon	beta	therapy	required	
patients to have accumulated a certain amount of disability to be eli-
gible	for	treatment.	However,	data	have	since	then	proven	the	benefit	
of	 early	 initiated	 interferon	 treatment	 (Kappos,	 Kuhle,	 et	al.,	 2015),	
exposing the rigid treatment criteria in the late 1990s to be scientifi-
cally	unjustified,	however,	somehow	rationalized	through	clinical	ex-
perience.	Retrospectively,	it	proved	itself	to	be	a	clinical	paradox	that	
the window of opportunity for obtaining maximum benefit from the 
DMT was narrowed considerably over time. On one hand a patient 
with	 little	or	no	current	disease	activity	 (i.	e.,	 relapse)	was	 ineligible	
to	receive	interferon	beta,	however,	after	subsequently	experiencing	
disability	progression	 following	a	 relapse,	 the	patient	was	at	 risk	of	
having missed the opportunity for receiving disease modifying treat-
ment.	Fortunately,	 treatment	with	 interferon	beta	 is	 initiated	earlier	
(Kappos,	Kuhle,	et	al.,	2015).
2.1 | Reorganizing MS outpatient care
The introduction of interferon beta therapies called for a reorgani-
zation	of	the	outpatient	care	 in	MS.	 In	Denmark,	biannual	follow-
 up visits were introduced in the out- patient MS clinics. Before the 
reorganization,	outpatient	care	and	follow-	up	were	determined	by	
the occurrence of relapses and need for symptomatic treatment 
only.	With	the	introduction	of	DMTs,	continuous	and	more	frequent	
follow-	up	was	also	generally	introduced,	improving	the	overall	care,	
nursing,	 and	 clinical	 follow-	up.	 Today	 the	 follow-	up	 introduced	
in the mid- 1990s has become the standard at many MS clinics. 
Treatment with interferon beta should be followed by clinical ex-
amination	 and	 blood	 tests	 including	 hemoglobin,	 leukocytes	with	
differential	count,	liver	enzymes,	serum	creatinine,	and	electrolytes	
after	3	and	6	months,	and	 then	every	6	months.	Measurement	of	
neutralizing	antibodies	should	be	performed	every	6	months	for	the	
first	2	years	of	treatment.	In	the	event	that	all	tests	for	neutralizing	
antibodies	during	this	period	have	been	negative,	monitoring	may	
stop,	as	the	probability	of	developing	neutralizing	antibodies	after	
this	time	is	minute	(Sorensen,		Koch-Henriksen,	Ross,	Clemmesen,	&	
Bendtzen,	2005).	Signs	of	disease	activity	should	reactivate	moni-
toring	of	neutralizing	antibodies.	Patients	should	be	clinically	evalu-
ated	after	2	years	of	treatment,	and	long-	term	treatment	should	be	
decided on an individual basis by the treating physician. Treatment 
should be discontinued if the patient develops chronic progressive 
MS	(Sorensen	et	al.,	2005).
2.2 | Pharmacodynamic properties of interferons 
in MS
Interferons are a family of naturally occurring proteins that are pro-
duced by eukaryotic cells in response to viral infection and other 
biological inducers. Interferons are cytokines that mediate anti-
viral,	 anti-	proliferative,	 and	 immunomodulatory	 activities.	 Three	
major	forms	of	interferons	have	been	distinguished:	alpha,	beta,	and	
gamma. Interferons alpha and beta are classified as Type I interfer-
ons and interferon gamma is a Type II interferon. These three types 
of interferons have overlapping but clearly distinguishable biological 
activities. Notably the systemic administration of gamma interferon 
has pronounced effects on cellular immunity in MS and on disease 
activity	within	 the	CNS,	 suggesting	 that	 the	 attacks	 induced	during	
treatment	with	interferon	gamma	are	immunologically	mediated,	leav-
ing interferon gamma unsuitable for use as a therapeutic agent in MS 
(Panitch,	Hirsch,	Schindler,	&	Johnson,	1987).	The	interferons	also	dif-
fer with respect to their cellular sites of synthesis. Interferon beta is 
produced by various cell types including fibroblasts and macrophages. 
Natural interferon beta is glycosylated and has a single N- linked com-
plex carbohydrate moiety. Glycosylation of other proteins is known 
to	affect	their	stability,	activity,	bio-	distribution,	and	half-	life	in	blood.	
However,	 the	effects	of	 interferon	beta	 that	are	dependent	on	gly-
cosylation are not fully defined. Interferon gamma is induced by the 
stimulation	of	sensitized	lymphocytes	with	antigen	or	non-	sensitized	
lymphocytes with mitogens.
The	mechanism	of	action	of	interferon	beta	is	complex,	involving	
effects at multiple levels of cellular function. Interferon beta appears 
to directly increase expression and concentration of anti- inflammatory 
agents while downregulating the expression of proinflammatory cyto-
kines. Interferon beta exerts its biological effects by binding to spe-
cific receptors on the surface of human cells. This binding initiates a 
complex cascade of intracellular events that leads to the expression 
of numerous interferon- induced gene products and markers. These 
include	 MHC	 Class	 I,	 Mx	 protein,	 2′/5′-	oligoadenylate	 synthetase	
(OAS),	β2-	microglobulin,	and	neopterin.	Some	of	these	products	have	
been measured in the serum and cellular fractions of blood collected 
from	patients	treated	with	interferon	beta	(Figure	1).
After	a	single	intramuscular	(IM)	dose	of	interferon	beta-	1a,	serum	
levels of these products remain elevated for at least 4 days and up to 
1	week	(Wiendl	&	Kieseier,	2003).	Whether	the	mechanism	of	action	
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of interferon beta in MS is mediated by the same pathway as the bio-
logical effects described here is not known.
Increased amounts of neopterin are produced by human mono-
cytes/macrophages upon stimulation of interferon beta. Measurement 
of	neopterin	 concentrations	 in	body	 fluids	 like	 serum,	 cerebrospinal	
fluid	or	urine,	provides	information	about	activation	of	T-	helper	cell	1	
derived	cellular	immune	activation	(Murr,	Widner,	Wirleitner,	&	Fuchs,	
2002) and pharmacological activity of interferon betas is assessed by 
serum	concentrations	of	neopterin	as	a	well-	characterized	biomarker	
induced	 by	 interferon	 beta-	1a	 and	 peginterferon	 beta-	1a	 (Bagnato,	
Durastanti,	Finamore,	Volante,	&	Millefiorini,	2003;	Hu	et	al.,	2011).	
A	small	study	furthermore	suggests	that	neopterin	may	be	considered	
a	 useful	 biomarker	 of	 interferon	 beta	 responsiveness	 (Casoni	 et	al.,	
2004).	2′5′	OAS	is	also	used	as	an	established	biomarker	of	interferon	
beta	activity	(Scagnolari	et	al.,	2007).
3  | ASSESSMENTS OF BENEFITS AND RISKS
Multiple sclerosis treatment has become widely differentiated and in-
dividually tailor- made with several treatment alternatives with various 
modes	of	action	and	administration.	Still,	interferon	betas	remain	the	
choice	of	treatment	for	many	patients.	In	particular,	 in	patients	who	
value the long- term safety profile of interferon betas and for young 
females the interferon betas may provide an attractive alternative to 
the	second	and	third	generation	MS	treatments,	which	are	contrain-
dicated	before	or	at	the	occurrence	of	pregnancy	(Amato	&	Portaccio,	
2015).
The consistent long- term safety data on interferon betas have 
over the years added to a favorable benefit/risk profile. The most fre-
quently	occurring	adverse	effects	with	 interferon	betas	are	injection	
site reactions and flu- like symptoms. Injection site reactions occur 
frequently	for	subcutaneous	(SC)	injections	but	less	frequently	for	IM	
injections.	Flu-	like	symptoms	tend	to	be	most	pronounced	at	the	initi-
ation	of	the	treatment	and	wears	off	over	time.	Flu-	like	symptoms	may	
be countered or reduced by symptomatic treatment with nonsteroidal 
anti-	inflammatory	drugs	or	paracetamol,	 and	additionally	dose	 titra-
tion recommendations may apply to the individual interferon betas for 
improved	 tolerability	 (SmPC	Avonex,	 2016;	 SmPC	Betaferon,	 2016;	
SmPC	Plegridy,	2014;	SmPC	Rebif,	2015).
Several interferon betas are approved and commercially available 
for	the	treatment	of	RRMS,	and	the	individual	products	differ	in	for-
mulation,	 dosing,	 administration,	 and	benefits/risk	 profiles	 including	
the	risk	of	developing	neutralizing	antibodies.
F IGURE  1 Mechanisms	of	action	for	IFNβ in multiple sclerosis. Interferon beta exerts its biological effects by binding to specific receptors on 
the surface of human cells. This binding initiates a complex cascade of intracellular events that leads to the expression of numerous interferon- 
induced	gene	products	and	markers	(Wiendl	&	Kieseier,	2003)
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Table 1 offers an overview of licensed interferon betas for the 
treatment of RRMS.
Heterogeneity	 of	 the	 disease	 and	 the	 natural—progressive—
course of RRMS may lead to periods of disease activity and the 
question	is	whether	this	may	be	caused	by	lack	of	response	to	the	
therapy.	 Clinically,	 this	 calls	 for	 analysis	 of	 neutralizing	 antibod-
ies.	The	development	of	 neutralizing	 antibody	 activity	 suggests	 a	
reduction	 in	clinical	efficacy,	and	there	 is	an	evident	rationale	for	
therapy	switch	or	treatment	discontinuation	(Sorensen	et	al.,	2003).	
With the expanded panel of treatment this may be less of an issue 
for	most	patients,	however,	in	young	women	who	wish	to	become	
pregnant,	 this	may	be	a	challenge,	particularly	 if	 they	have	previ-
ously	developed	neutralizing	antibodies,	since	interferon	betas	are	
considered the safer treatment choice in this cohort of patients. 
Thus,	there	is	still	a	mandate	to	consider	the	risk	of	development	of	
neutralizing	antibodies	when	evaluating	therapy	options.
4  | INNOVATIVE FORMULATIONS 
COUNTER ADHERENCE ISSUES
Interferon beta is a part of the first- line treatment of MS and is injected 
intramuscularly	or	subcutaneously.	Administration	may	be	associated	
with	discomfort	 from	 the	 injection,	 in	 addition	 to	potential	 adverse	
effects following dosing. The proportion of patients who do not fol-
low	the	treatment	according	to	the	prescription	(i.e.,	is	nonadherent)	
in	injectable	therapies	for	MS	is	estimated	to	be	15%–60%	(Costello,	
Kennedy,	 &	 Scanzillo,	 2008;	Devonshire	 et	al.,	 2011;	Menzin	 et	al.,	
2013).	Notwithstanding	 the	nature	of	 the	disease,	 nonadherence	 is	
a significant problem for the individual patient who does not achieve 
full	 effect	of	 the	 treatment	 (Sabate	&	De,	2004),	 and	 increases	 the	
risk	of	 relapses	 (Steinberg,	Faris,	Chang,	Chan,	&	Tankersley,	2010).	
Additionally,	nonadherence	constitutes	an	economic	burden	to	soci-
ety	 in	the	treatment	of	MS,	risking	that	the	underlying	disease	pro-
gresses	more	rapidly	(Steinberg	et	al.,	2010).
More	 recently,	 interferon	beta	has	been	modified	via	pegylation	
resulting in a prolonged half- life of the active substance while the 
TABLE  1 Commercially available interferons approved for the treatment of RRMS
Product
Active 
substance Adm. Dosing PK assessments Qualitative composition
Neutralizing  
antibodies
Reduction of the annual attack 
rate (ITT)*
Reduction of disability progression 
(EDSS)†
Common adverse effects
ReferencesFlu- like symptoms
Injection site 
reactions
Plegridy® Pegylated 
IFN	beta-	1a
SC 125	μg/2 weeks T½:	78	±	15	hr
Tmax:	1–1.5	days	(SmPC	Plegridy)
Recombinant from CHO- K1 
covalently linked with 
methoxy- polyethyleneglycol 
(SmPC Plegridy)
<1% (SmPC Plegridy) 36%	(Calabresi	et	al.,	2014) 38%	(12	w-	CDP;	Calabresi	et	al.,	
2014)
54%	(24	w-	CDP;	SmPC	Plegridy,	
2014)
47%	(SmPC	Plegridy,	
2014)
66%	(SmPC	Plegridy,	
2014)
SmPC
Calabresi et al. (2014)
Kieseier et al. (2014)
Betaferon®/
Extavia®
IFN	beta-	1b SC 250	μg/every 
other day
T½:	5	hr
Tmax:	1–8	hr
Bioavailability:	~50%	 
(SmPC Betaferon)
Recombinant from Escherichia 
coli (SmPC Betaferon)
23%–41%	 
(SmPC Betaferon)
30%	(The	IFNB	Multiple	Sclerosis	
Study	Group,	1993)
31%	(The	IFNB	Multiple	Sclerosis	
Study	Group,	1993)	(12	w-	CDP;	
SmPC	Betaferon,	2016)	NS
52%	(SmPC	Betaferon,	
2016)
85%	(SmPC	Betaferon,	
2016)
SmPC
The	IFNB	Multiple	Sclerosis	
Study Group (1993)
Avonex® IFN	beta-	1a IM 30 μg weekly T½: 10 hr
Tmax:	5–15	hr
Bioavailability:	~40%	(SmPC	Avonex)
Recombinant from CHO- K1 
(SmPC	Avonex)
5%–8%	(SmPC	Avonex) 32%	(Jacobs	et	al.,	1996) 37%	(24	w-	CDP;	Jacobs	et	al.,	1996) 61%	(Jacobs	et	al.,	1996) 15%	(Jacobs	et	al.,	
1996)
SmPC
Jacobs et al. (1996)
Rudick et al. (1997)
Rebif® IFN	beta-	1a SC 22 μg 3 × weekly
44 μg 3 × weekly
Apparent	T½:	50–60	hr
Tmax:	8	hr	(SmPC	Rebif,	2015)
Recombinant from CHO- K1 
(SmPC	Rebif,	2015)
24%	(SmPC	Rebif,	2015)
13-	14%	(SmPC	Rebif,	2015)
27%	(PRISMS	Study	Group,	1998)
33%	(PRISMS	Study	Group,	1998)
30%	(12w-	CDP;	SmPC	Rebif,	2015) 
39%	(12w-	CDP;	SmPC	Rebif,	2015)
70%	(SmPC	Rebif,	2015) 30%	(SmPC	Rebif,	
2015)
SmPC
PRISMS	Study	Group,	(1998)
The	data	are	extracted	from	the	respective	summary	of	product	characteristics	and	the	pivotal	registration	studies	performed	in	RRMS.	IFN,	Interferon;	 
T½,	half-	life	assessed	with	neopterin;	Tmax,	time	to	peak	concentration	assessed	with	neopterin;	CHO-	K1,	Chinese	hamster	ovary	cells;	ITT,	intention- 
	to-	treat.	SC,	subcutaneous;	IM,	intramuscular	ITT,	intention-	to-	treat	analysis;	CDP,	confirmed	disability	progression.	Data	in	the	columns	Active	 
substance,	Administration,	Dosing,	PK	assessments,	Qualitative	composition	and	neutralizing	antibodies	are	collected	from	the	respective	Summary	of	 
Product	Characteristics	(SmPC).	NS,	not	significant.
*Compared to placebo.
†Proportion	with	≥1-	point	progression	on	EDSS.
F IGURE  2 Pegylation implies addition of a polyethylene chain to 
an interferon beta- 1a molecule
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dosage	 interval	 is	extended,	allowing	for	fewer	 injections,	 less	accu-
mulated	discomfort	and	improved	adherence	of	treatment	(Figure	2).	
Pegylation	 stabilizes	 the	 molecule	 chemically	 by	 protecting	 it	 from	
degradation	 and	 proteolysis	 (Kang,	 Deluca,	 &	 Lee,	 2009).	 The	 in-
creased circulation time improves bioavailability and prolongs the half- 
life	of	the	active	substance,	implying	a	potential	beneficial	impact	on	
efficacy	(Hu	et	al.,	2015).
The slower degradation has also been shown to decrease the 
probability	 of	 developing	neutralizing	 antibodies	 (Kang	et	al.,	 2009).	
Altogether,	the	changed	properties	and	pharmacodynamic	effects	of	
PEGylated interferon (peginterferon) represent a new era of DMTs for 
RRMS (Table 1).
5  | PHARMACOKINETIC AND 
PHARMACODYNAMIC PROFILE OF 
PEGINTERFERON BETA
Compared to interferon beta- 1a 30 μg IM the half- life of peginter-
feron	 beta-	1a	 125	μg	 SC	 is	 longer	 (10	hr	 and	 2–3	days,	 respec-
tively;	Hu,	Miller,	&	Richman,	2012;	Hu	et	al.,	2015;	SmPC	Avonex,	
2016). The serum concentration of peginterferon beta- 1a appears 
to	be	dose	proportional	in	the	range	of	63–188	μg as observed in a 
single	and	multiple	dose	study	in	healthy	subjects	(Hu	et	al.,	2012).	
The pharmacokinetics observed in people with MS was similar to 
the	 pharmacokinetics	 in	 healthy	 subjects	 (Hu	 et	al.,	 2011,	 2012,	
2015).
In a phase 1 study of peginterferon beta- 1a multiple doses were 
administered	 subcutaneously	with	dosing	 intervals	of	2	 (Q2W)	and	4	
(Q4W)	weeks.	Biomarkers	 shown	 in	 these	clinical	 trials	demonstrated	
a stronger and prolonged response in administration of peginterferon 
beta-	1a	 than	 by	 non-	pegylated	 interferon	 beta1a	 (Hu	 et	al.,	 2012).	
Subcutaneous peginterferon beta- 1a resulted in ninefold higher ex-
posure	 (AUC168 hr)	 3.5-	fold	 higher	 Cmax,	 following	 single	 doses	 of	
125	μg(12	MIU),	compared	to	IM	administration	of	30	μg	(6	MIU)	non-	
pegylated beta- 1a. The extended dosing interval with peginterferon 
beta-	1a	gave	no	unexpected	adverse	events,	no	signs	of	accumulation	
of peginterferon beta- 1a and no loss of pharmacological properties at 
repeated	dosing	(Hu	et	al.,	2012).	Pegylation	resulted	in	increased	activ-
ity in vivo,	resulting	in	an	extended	half-	life	and	increased	bioavailability.
Recently,	 a	 comparative	 pharmacokinetic	 study	 demonstrated	 that	
one dose of SC peginterferon beta- 1a delivered significantly greater 
drug	 exposure	 than	 SC	 interferon	 beta-	1a,	 44	 μg	 three	 times	 a	week,	
over	2	weeks	and	a	 lower	frequency	of	adverse	events	 (AEs)	 (Hu	et	al.,	
2016).	The	 COMPARE	 study	was	 an	 open-	label,	 crossover,	 pharmaco-
kinetic study evaluating drug exposure and the safety and tolerability of 
SC	peginterferon	beta-	1a,	125	μg	and	SC	interferon	beta-	1a,	44	μg three 
times	a	week,	over	2	weeks	 in	healthy	subjects.	Thirty	healthy	subjects	
received	one	dose	of	peginterferon	beta-	1a	(125	μg SC) or six doses of 
interferon beta- 1a (44 μg	 SC)	 over	 2	weeks,	 followed	 by	 the	 alternate	
treatment after a 2- week washout period. Drug concentrations were 
measured	 using	 an	 enzyme-	linked	 immunosorbent	 assay	 and	 PK	 pa-
rameters including cumulative area under the concentration time curve 
(AUC336 hr) over 2 weeks and maximum observed serum concentrations 
(Cmax) were estimated using a non- compartmental analysis. The PK analy-
sis population comprised 26 subjects for each treatment. Cmax	was	3.5-	
fold higher with one dose of peginterferon SC (944 pg/ml) than after six 
doses	of	interferon	beta	SC	(266	pg/ml)	(Hu	et	al.,	2016).	Drug	exposure	
(AUC336 hr) was 60% higher with SC peginterferon beta- 1a than with SC 
interferon	beta-	1a	(117.4	[95%	confidence	interval	95.6–144.3]	hr·ng/ml	
vs.	 73.1	 [61.2–87.3]	hr·ng/ml,	 respectively;	p	<	.0001)	 (Hu	et	al.,	 2016).	
Injection-	site	reactions	(ISRs)	were	the	most	common	AEs	observed	with	
both	 treatments.	Numerically	 lower	 frequencies	 and	 incidence	 rates	 of	
ISRs,	headache,	myalgia,	and	chills,	were	observed	with	SC	peginterferon	
	beta-	1a	(Hu	et	al.,	2016).
Due to the reduced number of injections that peginterferon beta- 1a 
offers,	the	frequencies	of	injection	site	reactions	and	flu-	like	symptoms	
were numerically higher with SC interferon- beta- 1a treatment com-
pared	with	SC	peginterferon	beta-	1a	treatment	(Hu	et	al.,	2016).
Conclusively,	 the	 study	 demonstrated	 that	 peginterferon	 be-
ta-	1a	provided	significantly	greater	drug	exposure,	following	a	single	
dose,	compared	to	six	doses	of	SC	interferon	beta-	1a	over	2	weeks.	
TABLE  1   (Continued)
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Moreover,	 higher	 drug	 exposure	was	 not	 associated	with	 increased	
incidence of side effects; peginterferon beta- 1a demonstrated an im-
proved tolerability profile with respect to injection site reactions and 
flu-	like	symptoms	(Figure	3).
6  | CLINICAL EFFECTS OF PEGINTERFERON 
BETA- 1A
In	 the	ADVANCE	 study,	 a	 2-	year	 double-	blind,	 parallel	 group,	 phase	
3	 study	enclosing	a	placebo	controlled	design	 for	 the	 first	48	weeks,	
peginterferon	beta-	1a	given	Q2W	significantly	reduced	the	relapse	rate	
compared	with	placebo	(Calabresi	et	al.,	2014).	The	adjusted	annualized	
relapse	 rates	 (ARR)	were	0.397	 (95%	CI	0.328–0.481)	 in	 the	placebo	
group	versus	0.256	(0.206–0.318)	in	Q2W	group	(rate	ratio	for	Q2W	
0.644,	95%	CI	0.500–0.831,	p	=	.0007),	corresponding	to	a	relative	risk	
reduction	in	ARR	of	36%	at	Year	1	(Calabresi	et	al.,	2014).	Peginterferon	
beta- 1a reduced 12- week and 24- week confirmed disability progres-
sion by 38% (p	=	.0383)	versus	placebo	at	Year	1	(Calabresi	et	al.,	2014);	
while the 24- week confirmed disability progression for the peginter-
feron	beta-	1a	group	was	54%	(p	=	.0069;	SmPC	Plegridy,	2014).
In	 the	 second	 year	 of	ADVANCE,	 all	 placebo	 patients	were	 re-	
randomized	to	either	peginterferon	beta-	1a	Q2W	or	Q4W	(Kieseier	
et	al.,	 2014).	 Compared	 to	Year	 1,	 the	ARR	was	 further	 reduced	 in	
Year	2	with	Q2W	dosing	(Year	1:	0.230	[95%	CI	0.183–0.291],	Year	
2:	0.178	[0.136–0.233];	Kieseier	et	al.,	2014).	Patients	starting	pegin-
terferon	beta-	1a	Q2W	from	Year	1	displayed	improved	efficacy	ver-
sus	patients	 initially	assigned	placebo,	with	reductions	 in	ARR	(37%,	
p	<	.0001),	 risk	 of	 relapse	 (39%,	 p	<	.0001),	 12-	week	 disability	 pro-
gression	 (33%,	p	=	.0257),	 and	24-	week	disability	progression	 (41%,	
p	=	.0137;	Kieseier	et	al.,	2014).
83% of patients taking placebo and 94% of patients taking pegin-
terferon	beta-	1a	Q2W	reported	adverse	events	including	relapses.	The	
most common adverse events associated with peginterferon beta- 1a 
were	 injection	 site	 reactions,	 flu-	like	 symptoms,	 pyrexia,	 and	 head-
ache.	76	(15%)	patients	taking	placebo,	11%	of	patients	taking	study	
drug	Q2W	reported	serious	adverse	events;	relapse,	pneumonia,	and	
urinary tract infection were the most common; with apparently fewer 
flu-	like	symptoms	in	comparison,	the	overall	safety	profile	of	peginter-
feron beta- 1a seems to resemble that of other interferon beta thera-
pies	(Calabresi	et	al.,	2014;	Kieseier	et	al.,	2014).
In	 the	ADVANCE	 study	 1332	 (88%)	 of	 1,512	 participants	 com-
pleted	the	first	year	of	the	study.	Treatment	adherence—defined	as	the	
number of doses a patient received divided by the number they were 
expected	to	have	received—was	greater	than	99%	in	each	treatment	
group	(Calabresi	et	al.,	2014).
Although	direct	head-	to-	head	studies	have	not	been	conducted,	
the data suggest that the improved PK/PD profile of peginterferon 
beta- 1a may confer comparable clinical effects as non- pegylated in-
terferon	beta,	but	with	a	formulation	that	offers	prolonged	injection	
intervals. Patients thus have an effective interferon beta treatment 
option	that	also	significantly	reduces	the	number	of	 injections,	 from	
up	to	156	to	 just	26	per	year	with	a	minimum	risk	of	developing	of	
neutralizing	 antibodies	 (Calabresi	 et	al.,	 2014;	 Kieseier	 et	al.,	 2014).	
Furthermore,	this	feature	improves	the	user-	friendliness	of	the	ther-
apy,	allowing	a	significantly	lower	number	of	injections.
7  | MAGNETIC RESONANCE IMAGING
Post	hoc	analyses	of	the	efficacy	of	peginterferon	beta-	1a	Q2W	ver-
sus	Q4W	were	conducted	for	clinical	and	MRI	endpoints	over	2	years.	
Over	 2	years,	 peginterferon	 beta-	1a	Q2W	produced	 favorable	MRI	
outcomes	compared	with	peginterferon	beta-	1a	Q4W	(Kieseier	et	al.,	
2014).	 The	 results	 enclose	 a	 T2-	weighted	 lesion	 mean	 ratio	 Q2W	
versus	Q4W	of	0.40	(95%	CI	0.32,	0.49)	p < .0001) and a percentage 
reduction of gadolinium enhanced lesions at 2 years in the group of 
Q2W	versus	Q4W:	71%	reduction;	p < .00001.
8  | FUTURE PROSPECTS
Interferon beta is a treatment that has been used for many years in 
MS,	however,	developments	in	this	efficacious	treatment	have	con-
tinued	over	the	years,	with	pegylation	as	the	most	recent	innovation.	
The data on peginterferon beta- 1a have demonstrated this new in-
terferon beta to be an effective treatment with an attractive benefit/
risk profile and with a markedly lessened injection burden compared 
to	non-	PEGylated	formulations	(Calabresi	et	al.,	2014;	Kieseier	et	al.,	
2014).	With	 improved	innovative	formulations,	there	 is	a	possibility	
that	 efficacy,	 administration	 frequency,	 and	 adherence	 rates	 may	
improve.
F IGURE  3 Peginterferon beta- 1a yields 
a higher overall drug exposure compared 
to subcutaneous (SC) interferon beta- 1a. 
The curve demonstrates a higher overall 
drug exposure with peginterferon beta- 1a 
compared to SC interferon beta- 1a (Hu 
et	al., 2016)
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